Latest Close
$24.21
Stock Hub
ARQT
Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. Use the sections below to move between chart, technical analysis, fundamentals, and news.
1y Change
$11.62 (+92.30%)
Market Cap
$3B
Sector
Healthcare
Industry
Biotechnology
Recommendation
strong_buy
52W Range
$12.42 to $31.77
Target Mean Price
$34.75
Beta
1.77
Trailing P/E
Not available
Forward P/E
18.94
Price / Book
15.76
Company Overview
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.